AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1568660 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid (CDCA, 12 mg/kg/day)
Number of subjects: 48
Study 1568660 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime administration of UDCA
Number of subjects: 48
Study 1568660 — intervention group
Group type: EXPERIMENTAL
Intervention: Mealtime administration of UDCA
Number of subjects: 48
Study 1568660 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (CDCA 6 mg/kg/day + UDCA 6 mg/kg/day at bedtime)
Number of subjects: 48
Study 1568660 — intervention group
Group type: COMPARATOR
Intervention: CDCA alone
Number of subjects: 48
Study 2866777 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg temazepam
Number of subjects: 32
Study 2866777 — intervention group
Group type: COMPARATOR
Intervention: 2 mg flunitrazepam
Number of subjects: 32
Study 31780130 — intervention group
Group type: EXPERIMENTAL
Intervention: iCBT (internet-delivered cognitive behavioural therapy)
Number of subjects: 391
Study 30526264 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine patch
Number of subjects: 33
Study 30526264 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 33
Study 28249134 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Number of subjects: 1203
Study 28249134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1203
Study 24706493 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 4 to 8 mg
Number of subjects: 0
Study 24706493 — intervention group
Group type: COMPARATOR
Intervention: Non-escalators
Number of subjects: 0
Study 24253810 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin + cyclophosphamide followed by docetaxel + bevacizumab
Number of subjects: 212
Study 24253810 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel + doxorubicin + cyclophosphamide + bevacizumab
Number of subjects: 212
Study 24253810 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel + carboplatin + trastuzumab + bevacizumab
Number of subjects: 212
Study 24253810 — intervention group
Group type: EXPERIMENTAL
Intervention: All arms received bevacizumab
Number of subjects: 212
Study 22120090 — intervention group
Group type: COMPARATOR
Intervention: Tolvaptan 15-120 mg single dose
Number of subjects: 100
Study 22120090 — intervention group
Group type: COMPARATOR
Intervention: Tolvaptan 30-120 mg once daily for 7 days
Number of subjects: 100
Study 22120090 — intervention group
Group type: COMPARATOR
Intervention: Tolvaptan 60 mg and above
Number of subjects: 100
Study 22120090 — intervention group
Group type: COMPARATOR
Intervention: Tolvaptan
Number of subjects: 100
Study 19101459 — intervention group
Group type: COMPARATOR
Intervention: Condoms only
Number of subjects: 1952
Study 19101459 — intervention group
Group type: EXPERIMENTAL
Intervention: No effective method
Number of subjects: 1952
Study 19101459 — intervention group
Group type: EXPERIMENTAL
Intervention: OC only
Number of subjects: 1952
Study 19101459 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual OC and condoms
Number of subjects: 1952
Study 19101459 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency contraception
Number of subjects: 1952
Study 18219850 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab alone therapy (A-group)
Number of subjects: 18
Study 18219850 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus taxane therapy (B-group)
Number of subjects: 18
Study 18219850 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus taxane therapy (after addition to A-group)
Number of subjects: 18
Study 14976789 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical team changed gloves after delivery of the placenta
Number of subjects: 92
Study 14976789 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgical gloves not changed)
Number of subjects: 92
Study 11310943 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36
Number of subjects: 6921
Study 11310943 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 components
Number of subjects: 6921
Study 9333181 — intervention group
Group type: COMPARATOR
Intervention: Sb alone for 30 days (group A)
Number of subjects: 156
Study 9333181 — intervention group
Group type: EXPERIMENTAL
Intervention: Sb plus IFN‐gamma for 30 days (group B)
Number of subjects: 156
Study 9333181 — intervention group
Group type: EXPERIMENTAL
Intervention: Sb plus IFN‐gamma for 15 days (group C)
Number of subjects: 156
Study 7631088 — intervention group
Group type: EXPERIMENTAL
Intervention: VPL pallidotomy
Number of subjects: 0
Study 7631088 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-sided VPL thalamotomy
Number of subjects: 0
Study 7631088 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventrolateral thalamotomy
Number of subjects: 0
Study 3605748 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental treatment (EEG suppression)
Number of subjects: 31
Study 3605748 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane treatment (EEG suppression)
Number of subjects: 31
Study 3605748 — intervention group
Group type: COMPARATOR
Intervention: Control (no further anesthetics during bypass and continuous EEG activity)
Number of subjects: 31
Study 29952443 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD inhaler instruction
Number of subjects: 21
Study 29952443 — intervention group
Group type: COMPARATOR
Intervention: Individual education with a physiotherapist
Number of subjects: 21
Study 28672405 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term antidepressant treatment (SSRI/SNRI) for 6-52 weeks
Number of subjects: 0
Study 28672405 — intervention group
Group type: EXPERIMENTAL
Intervention: No antidepressant treatment (with or without benzodiazepine medication)
Number of subjects: 0
Study 28672405 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 25537835 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted insulin aspart (20 U/ml)
Number of subjects: 11
Study 25537835 — intervention group
Group type: COMPARATOR
Intervention: Standard insulin aspart (100 U/ml)
Number of subjects: 11
Study 23866779 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinus membrane elevation without bone grafting
Number of subjects: 14
Study 23866779 — intervention group
Group type: COMPARATOR
Intervention: Sinus membrane elevation with bone grafting
Number of subjects: 14
Study 21943105 — intervention group
Group type: EXPERIMENTAL
Intervention: Needling at BL33
Number of subjects: 100
Study 21943105 — intervention group
Group type: COMPARATOR
Intervention: Needling at non-point (control)
Number of subjects: 100
Study 18279058 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus FOLFOX-4
Number of subjects: 2000
Study 18279058 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX-4 alone
Number of subjects: 2000
Study 16780768 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating Laryngeal Mask Airway (ILMA)
Number of subjects: 53
Study 16780768 — intervention group
Group type: COMPARATOR
Intervention: Direct Laryngoscope (DLS)
Number of subjects: 53
Study 15181098 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion
Number of subjects: 31
Study 10799353 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid (500 mg)
Number of subjects: 24
Study 10799353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8957583 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg once daily
Number of subjects: 133
Study 8957583 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg twice daily
Number of subjects: 133
Study 1416131 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg intravenous metoclopramide
Number of subjects: 32
Study 1416131 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 32
Study 2987133 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulbactam-ampicillin
Number of subjects: 103
Study 2987133 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 103
Study 29325171 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal and Child Health Handbook (MCHHB) provision at antenatal care visits; records and guides by health personnel; sensitization of care by volunteers
Number of subjects: 454
Study 29325171 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal and Child Health Handbook (MCHHB) use
Number of subjects: 454
Study 29058084 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF + PRF
Number of subjects: 24
Study 29058084 — intervention group
Group type: COMPARATOR
Intervention: CAF
Number of subjects: 24
Study 27354224 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 2305
Study 27354224 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 2305
Study 27354224 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF < 15%
Number of subjects: 2305
Study 24786613 — intervention group
Group type: EXPERIMENTAL
Intervention: POBC‐URSL
Number of subjects: 156
Study 22084206 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy CTPA (image reconstruction at 50 keV) with 50% reduction in iodine load (n = 48)
Number of subjects: 94
Study 22084206 — intervention group
Group type: COMPARATOR
Intervention: Standard CTPA (100-120 kVp) with standard contrast medium injection (n = 46)
Number of subjects: 94
Study 20815182 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery sleep doses of 0, 2, 4, 6, 8, or 10 h TIB after 5 nights of sleep restriction to 4 h TIB
Number of subjects: 159
Study 20815182 — intervention group
Group type: COMPARATOR
Intervention: 10 h TIB on all nights (control condition)
Number of subjects: 159
Study 19083445 — intervention group
Group type: EXPERIMENTAL
Intervention: BTE tablets (333 mg)
Number of subjects: 47
Study 16817011 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme Replacement Therapy (ERT)
Number of subjects: 15
Study 16817011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 12785023 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (ligation) followed by sclerotherapy (Group F)
Number of subjects: 0
Study 12785023 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam-sclerotherapy (Group E)
Number of subjects: 0
Study 12785023 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy (Group A)
Number of subjects: 0
Study 12785023 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose sclerotherapy (Group B)
Number of subjects: 0
Study 12785023 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple ligations (Group C)
Number of subjects: 0
Study 12785023 — intervention group
Group type: EXPERIMENTAL
Intervention: Stab avulsion (Group D)
Number of subjects: 0
Study 10716475 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (Ang II type 1 receptor antagonist)
Number of subjects: 23
Study 10716475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 9207725 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevel-down method
Number of subjects: 10
Study 9207725 — intervention group
Group type: COMPARATOR
Intervention: Bevel-up method
Number of subjects: 10
Study 8280514 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous monitoring of left ventricular function during exercise using a miniature nuclear probe (Cardioscint)
Number of subjects: 31
Study 3510333 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 82
Study 3510333 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 82
Study 31327040 — intervention group
Group type: EXPERIMENTAL
Intervention: Right access for PTBD (group A)
Number of subjects: 64
Study 31327040 — intervention group
Group type: COMPARATOR
Intervention: Left access for PTBD (group B)
Number of subjects: 64
Study 29525929 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived need for treatment
Number of subjects: 0
Study 29525929 — intervention group
Group type: EXPERIMENTAL
Intervention: Family factors (low cohesion and high conflict)
Number of subjects: 0
Study 29525929 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical factors (adolescent internalizing and externalizing symptomatology)
Number of subjects: 0
Study 29525929 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical and family factors
Number of subjects: 0
Study 26603892 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 30
Study 26603892 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study 24514907 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise training with 250 mg resveratrol
Number of subjects: 0
Study 24514907 — intervention group
Group type: COMPARATOR
Intervention: High-intensity exercise training with placebo
Number of subjects: 0
Study 24514907 — intervention group
Group type: COMPARATOR
Intervention: Resveratrol (250 mg)
Number of subjects: 0
Study 22395588 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% dexpanthenol (DT) ointment
Number of subjects: 30
Study 22395588 — intervention group
Group type: COMPARATOR
Intervention: 1% hydrocortisone (HC) ointment
Number of subjects: 30
Study 20808314 — intervention group
Group type: EXPERIMENTAL
Intervention: Siltuximab 3 mg/kg, q3w × 4
Number of subjects: 68
Study 20808314 — intervention group
Group type: EXPERIMENTAL
Intervention: Siltuximab 6 mg/kg, q3w × 4
Number of subjects: 68
Study 20808314 — intervention group
Group type: EXPERIMENTAL
Intervention: Siltuximab 6 mg/kg, q2w × 6
Number of subjects: 68
Study 19025059 — intervention group
Group type: EXPERIMENTAL
Intervention: Estalin 2 mg tablets (test formulation)
Number of subjects: 24
Study 19025059 — intervention group
Group type: COMPARATOR
Intervention: 2 mg tablets of the originator product (reference formulation)
Number of subjects: 24
Study 15998754 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard HIV testing
Number of subjects: 6000
Study 15998754 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid HIV testing
Number of subjects: 6000
Study 15998754 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antiretroviral regimens, elective cesarean section in selected patients, avoidance of breastfeeding
Number of subjects: 6000
Study 15998754 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-out testing policies
Number of subjects: 6000
Study 15998754 — intervention group
Group type: COMPARATOR
Intervention: Targeted screening based on risk factors
Number of subjects: 6000
Study 15998754 — intervention group
Group type: COMPARATOR
Intervention: Untreated HIV infection
Number of subjects: 6000
Study 12841803 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to direct-to-consumer advertisements for osteoporosis drugs
Number of subjects: 51
Study 11815322 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg elemental Zn/d in cherry syrup)
Number of subjects: 42
Study 11815322 — intervention group
Group type: COMPARATOR
Intervention: Control group (cherry syrup alone)
Number of subjects: 42
Study 10414395 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 69
Study 10414395 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP)
Number of subjects: 69
Study 8775955 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct referral to oral and maxillofacial surgery
Number of subjects: 0
Study 8775955 — intervention group
Group type: COMPARATOR
Intervention: Routine A&E procedure
Number of subjects: 0
Study 2139283 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 micrograms dose, 4 dose vaccination schedule
Number of subjects: 270
Study 2139283 — intervention group
Group type: COMPARATOR
Intervention: 40 micrograms dose, 3 dose vaccination schedule
Number of subjects: 270
Study 2139283 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 micrograms dose, 0, 1, 2, 6 month schedule
Number of subjects: 270
Study 2139283 — intervention group
Group type: COMPARATOR
Intervention: 40 micrograms dose, 0, 1, 2, 12 month schedule
Number of subjects: 270
Study 2139283 — intervention group
Group type: COMPARATOR
Intervention: 20 micrograms dose
Number of subjects: 270
Study 7018854 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg Ro 13-9904
Number of subjects: 45
Study 7018854 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg Ro 13-9904
Number of subjects: 45
Study 7018854 — intervention group
Group type: COMPARATOR
Intervention: 80 mg tobramycin
Number of subjects: 45
Study 6368877 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (200 mg) five times daily for five days
Number of subjects: 250
Study 6368877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 29017191 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile mindfulness training app '7mind' for 14 days
Number of subjects: 306
Study 29017191 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (access to the app after study)
Number of subjects: 306
Study 26302669 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadratus lumborum block
Number of subjects: 104
Study 26302669 — intervention group
Group type: COMPARATOR
Intervention: Femoral block
Number of subjects: 104
Study 26302669 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 104
Study 24906976 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (M) 2 g/day
Number of subjects: 90
Study 24906976 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (M) 2 g/day + Oral contraceptive pills (OCP) (150 mg desogestrel + 30 microgram ethinylestradiol)
Number of subjects: 90
Study 24906976 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptive pills (OCP)
Number of subjects: 90
Study 23061303 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 42
Study 23061303 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 42
Study 19924003 — intervention group
Group type: EXPERIMENTAL
Intervention: BOSU balance trainer (both sides)
Number of subjects: 20
Study 17891043 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard clinic‐based patient education (SC) plus structured proactive telephone calls
Number of subjects: 109
Study 17891043 — intervention group
Group type: COMPARATOR
Intervention: Standard clinic‐based patient education (SC)
Number of subjects: 109
Study 16866809 — intervention group
Group type: EXPERIMENTAL
Intervention: One-on-one teaching
Number of subjects: 67
Study 16866809 — intervention group
Group type: EXPERIMENTAL
Intervention: Group teaching
Number of subjects: 67
Study 16866809 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study 14702000 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MM)
Number of subjects: 11
Study 14702000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 10905421 — intervention group
Group type: EXPERIMENTAL
Intervention: Abuse-focused cognitive behavioral therapy
Number of subjects: 49
Study 10905421 — intervention group
Group type: COMPARATOR
Intervention: Nondirective supportive therapy
Number of subjects: 49
Study 9173335 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin (PHT)
Number of subjects: 64
Study 9173335 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 64
Study 10145582 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Spacer (OS)
Number of subjects: 16
Study 10145582 — intervention group
Group type: COMPARATOR
Intervention: Volumatic Spacer
Number of subjects: 16
Study 10145582 — intervention group
Group type: COMPARATOR
Intervention: Nebuhaler Spacer
Number of subjects: 16
Study 10145582 — intervention group
Group type: COMPARATOR
Intervention: Inspirease Spacer
Number of subjects: 16
Study 2408515 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg t.i.d. tritoqualine for three days
Number of subjects: 44
Study 2408515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 2408515 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg t.i.d. tritoqualine for three days (in patients with a history of allergy)
Number of subjects: 44
Study 2408515 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in patients with a history of allergy)
Number of subjects: 44
Study 30772941 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (50 mg daily in 6-week cycles: 4 weeks on treatment, 2 weeks off treatment)
Number of subjects: 1124
Study 28621083 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Communication Intervention Programme (SCIP)
Number of subjects: 5
Study 28621083 — intervention group
Group type: EXPERIMENTAL
Intervention: SCIP intervention
Number of subjects: 5
Study 27094801 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin with pulsed radiofrequency
Number of subjects: 60
Study 27094801 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin with sham treatment
Number of subjects: 60
Study 24657428 — intervention group
Group type: EXPERIMENTAL
Intervention: CF-guided CPVI
Number of subjects: 38
Study 24657428 — intervention group
Group type: COMPARATOR
Intervention: Non-CF-guided CPVI
Number of subjects: 38
Study 22383680 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL) plus adjuvant systemic therapy
Number of subjects: 96
Study 22383680 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant systemic therapy alone (Control)
Number of subjects: 96
Study 20440122 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-running training group (CTG)
Number of subjects: 63
Study 20440122 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent-running training group (ITG)
Number of subjects: 63
Study 20440122 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 63
Study 18990766 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum vitamin B6
Number of subjects: 278
Study 18990766 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum folate
Number of subjects: 278
Study 18990766 — intervention group
Group type: EXPERIMENTAL
Intervention: Other serum biomarkers (vitamin B12, riboflavin, homocysteine)
Number of subjects: 278
Study 18990766 — intervention group
Group type: EXPERIMENTAL
Intervention: A priori combinations of the five one-carbon serum biomarkers
Number of subjects: 278
Study 15817867 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamins (MV)
Number of subjects: 886
Study 15817867 — intervention group
Group type: EXPERIMENTAL
Intervention: Preformed vitamin A + beta-carotene (VA/BC)
Number of subjects: 886
Study 15817867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 886
Study 12859466 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1 microg.kg‐1 (group R)
Number of subjects: 40